RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer.
Harshabad SinghPranshu SahgalKevin S KapnerSteven M CorselloHersh V GuptaRahul GujrathiYvonne Y LiAndrew D CherniakRaquelle El AlamJoseph A KerfootElizabeth AndrewsAnnette LeeChetan NambiarAlison M HanniganJoshua RemlandLauren K BraisMeghan E LeahyDouglas A RubinsonBenjamin L SchlechterMatthew L MeyersonYanan KuangCloud P PaweletzJessica K LeeJulia Coelho França QuintanilhaAndrew J AguirreKimberley J PerezBrandon M HuffmanHumberto RossiThomas A AbramsSheheryar K KabrajiLivio TrusolinoAndrea BertottiEwa T SicinskaAparna Raj ParikhBrian M WolpinAlexa B SchrockMarios GiannakisKimmie NgJeffrey A MeyerhardtJason L HornickNilay S SethiJames M ClearyPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Co-occurring RAS/RAF alterations define a unique subtype of ERBB2-amplified colorectal cancer that has increased intratumoral heterogeneity, interlesional discordance, and resistance to trastuzumab-based combinations. Further examination of trastuzumab deruxtecan in this previously understudied cohort of ERBB2-amplified colorectal cancer is warranted.